N/A
Completed N=20
Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of Anti-inflammatory Effects
Healthy
Source: ClinicalTrials.gov NCT00874757 ↗
Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Aug 2024
Primary outcomePrimary: Toll-like Receptor 4 Expression Pre- and Post-Treatment — 12.37; 6.36 % tlr expression (monocytes)
Summary
The purpose of this study is to see whether Statin drugs will act as anti-inflammatories. The investigators will study this potential anti-inflammatory activity in healthy subjects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Toll-like Receptor 4 Expression Pre- and Post-Treatment |
12.37; 6.36 | — |
| SECONDARY Tumor Necrosis Factor (TNF) |
145; 92 | — |
| SECONDARY Interleukin-6 |
4.8; 4.1 | — |
| SECONDARY Interleukin-8 |
155; 125 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy male non-asian subjects
Exclusion Criteria
- Patients with increased liver function tests, elevated serum creatine, patients on anti-inflammatory or immunomodulating drugs
Data sourced from ClinicalTrials.gov (NCT00874757). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.